HP 129Xe MRI for Evaluation of CLAD in Lung Transplant Recipients

Status Recruiting

Clinical Trial Summary

To evaluate the feasibility of hyperpolarized 129Xe MRI in lung transplant recipients and assess structural and functional pulmonary changes using hyperpolarized 129Xe MRI

Clinical Trial Description

Lung transplantation is an effective treatment for end-stage lung disease. However, median survival post-LTx is 6 years. This is primarily due to chronic lung allograft dysfunction (CLAD). Clinical management of LTx recipients is focused on identifying early risk factors for CLAD, by monitoring graft function with spirometry and transbronchial biopsies. However, both have significant limitations. Hyperpolarized (HP) noble gas lung MRI (3He and 129Xe) allows mapping of both lung anatomy and function. 129Xe-MRI could provide a diagnostic tool that is able to detect CLAD more sensitively and earlier than the current gold standard measurements of spirometry and plethysmography, and thus allow a means to detect and prevent /slow down irreparable and irreversible damage to the lungs in the early stages of disease. ;

Study Design

Related Conditions & MeSH terms

Lung Transplant Rejection

Clinical Trial Details

NCT number	NCT05550662
Study type	Interventional
Source	The Hospital for Sick Children
Contact	Giles Santyr, PhD
Phone	416-813-7654
Email	giles.santyr@sickkids.ca
Status	Recruiting
Phase	Phase 2
Start date	February 7, 2024
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT06309628` - Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy
Withdrawn	`NCT02893176` - Macitentan in the Treatment of Organ Rejection After Lung Transplantation	Phase 4
Completed	`NCT02441413` - Transplant Optimization Using Functional Imaging (TROFI)	N/A
Recruiting	`NCT05375149` - Exhaled Breath Particles in Lung Transplantation
Active, not recruiting	`NCT03967340` - PREdiction of Chronic LUng Allograft Dysfunction
Active, not recruiting	`NCT05260372` - Next Generation Sequencing to Detect Acute Rejection in Lung Transplant Patients.
Recruiting	`NCT06082037` - A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction	Phase 3
Recruiting	`NCT04714801` - Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation	Phase 1/Phase 2
Active, not recruiting	`NCT05170425` - LAMBDA 002 (Lung Registry) Study
Completed	`NCT02474927` - Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation	Phase 2
Recruiting	`NCT05006742` - Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients	N/A
Recruiting	`NCT02812290` - Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation
Not yet recruiting	`NCT03500575` - Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients	N/A
Withdrawn	`NCT03805178` - Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization	Phase 2
Completed	`NCT03359863` - Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction	Phase 2
Active, not recruiting	`NCT03656926` - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)	Phase 3
Completed	`NCT01985412` - Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection
Completed	`NCT04234919` - Longitudinal Study of Cell Free DNA in Lung Transplant
Recruiting	`NCT04837339` - Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation	N/A
Recruiting	`NCT03090581` - Transbronchial Biopsies With Cryoprobe in Patients With Lung Transplantation.	N/A